3-(2-bromoacetyl)-7-fluoro-1H-isochromen-1-one | 1448704-72-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异香豆素及其衍生物
• 英文名称: 3-(2-bromoacetyl)-7-fluoro-1H-isochromen-1-one
• 英文别名: 1H-2-Benzopyran-1-one, 3-(2-bromoacetyl)-7-fluoro-；3-(2-bromoacetyl)-7-fluoroisochromen-1-one
• CAS: 1448704-72-0
• 化学式: C₁₁H₆BrFO₃
• 分子量: 285.069
• InChiKey: OOAQTRRBZGEYJK-UHFFFAOYSA-N

物化性质

• 沸点：
  399.9±42.0 °C(Predicted)
• 密度：
  1.741±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(2-bromoacetyl)-7-fluoro-1H-isochromen-1-one 以 N-甲基吡咯烷酮 、 乙腈 为溶剂， 反应 40.0h， 生成 3-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-7-(piperazin-1-yl)-1H-isochromen-1-one
  参考文献：
  名称：

  Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy

  摘要：

  The underlying cause of spinal muscular atrophy (SMA) is a deficiency of the survival motor neuron (SMN) protein. Starting from hits identified in a high-throughput screening campaign and through structure activity relationship investigations, we have developed small molecules that potently shift the alternative splicing of the SMN2 exon 7, resulting in increased production of the full-length SMN mRNA and protein. Three novel chemical series, represented by compounds 9, 14, and 20, have been optimized to increase the level of SMN protein by >50% in SMA patient-derived fibroblasts at concentrations of <160 nM. Daily administration of these compounds to severe SMA Delta 7 mice results in an increased production of SMN protein in disease-relevant tissues and a significant increase in median survival time in a dose-dependent manner. Our work supports the development of an orally administered small molecule for the treatment of patients with SMA.

  DOI：

  10.1021/acs.jmedchem.6b00460
• 作为产物：
  描述：

  3-acetyl-7-fluoro-1H-isochromen-1-one 在 溴 作用下， 以 氯仿 为溶剂， 反应 1.0h， 以96%的产率得到3-(2-bromoacetyl)-7-fluoro-1H-isochromen-1-one
  参考文献：
  名称：

  [EN] COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY
  [FR] COMPOSÉS DESTINÉS À TRAITER L'AMYOTROPHIE SPINALE

  摘要：

  本文提供了用于治疗脊髓性肌萎缩症的化合物、其组合物及其用途。

  公开号：

  WO2013112788A1

文献信息

• [EN] COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY<br/>[FR] COMPOSÉS DESTINÉS À TRAITER L'AMYOTROPHIE SPINALE
  申请人：PTC THERAPEUTICS INC

  公开号：WO2013112788A1

  公开（公告）日：2013-08-01

  Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy.

  本文提供了用于治疗脊髓性肌萎缩症的化合物、其组合物及其用途。
• COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY
  申请人：PTC Therapeutics, Inc.

  公开号：US20150126515A1

  公开（公告）日：2015-05-07

  Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy.

  本文提供了用于治疗脊髓肌肉萎缩症的化合物、其组合物和使用方法。
• US9399649B2
  申请人：——

  公开号：US9399649B2

  公开（公告）日：2016-07-26
• Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy
  作者：Matthew G. Woll、Hongyan Qi、Anthony Turpoff、Nanjing Zhang、Xiaoyan Zhang、Guangming Chen、Chunshi Li、Song Huang、Tianle Yang、Young-Choon Moon、Chang-Sun Lee、Soongyu Choi、Neil G. Almstead、Nikolai A. Naryshkin、Amal Dakka、Jana Narasimhan、Vijayalakshmi Gabbeta、Ellen Welch、Xin Zhao、Nicole Risher、Josephine Sheedy、Marla Weetall、Gary M. Karp

  DOI：10.1021/acs.jmedchem.6b00460

  日期：2016.7.14

  The underlying cause of spinal muscular atrophy (SMA) is a deficiency of the survival motor neuron (SMN) protein. Starting from hits identified in a high-throughput screening campaign and through structure activity relationship investigations, we have developed small molecules that potently shift the alternative splicing of the SMN2 exon 7, resulting in increased production of the full-length SMN mRNA and protein. Three novel chemical series, represented by compounds 9, 14, and 20, have been optimized to increase the level of SMN protein by >50% in SMA patient-derived fibroblasts at concentrations of <160 nM. Daily administration of these compounds to severe SMA Delta 7 mice results in an increased production of SMN protein in disease-relevant tissues and a significant increase in median survival time in a dose-dependent manner. Our work supports the development of an orally administered small molecule for the treatment of patients with SMA.